Cargando…
miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2
5-Fluorouracil (5FU)-based adjuvant therapy is the first-line therapy for treating stage II and III colon cancer after surgery. However, its therapeutic efficacy is limited because of chemoresistance, especially in deficient mismatch repair (dMMR) colon cancer. Here, we first used laser capture micr...
Autores principales: | Ye, Ling, Jiang, Tao, Shao, Huanzhang, Zhong, Lin, Wang, Zhaowen, Liu, Yuan, Tang, Huamei, Qin, Bingyu, Zhang, Xiaoqing, Fan, Junwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443909/ https://www.ncbi.nlm.nih.gov/pubmed/28624221 http://dx.doi.org/10.1016/j.omtn.2017.05.006 |
Ejemplares similares
-
Mismatch Repair Protein hMLH1, but not hMSH2, Enhances Estrogen-Induced Apoptosis of Colon Cancer Cells
por: Jin, Peng, et al.
Publicado: (2017) -
The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor α
por: Wada-Hiraike, O, et al.
Publicado: (2005) -
Expression of hMSH2 protein of the human DNA mismatch repair system in oral lichen planus
por: Pimenta, Flávio Juliano Garcia Santos, et al.
Publicado: (2004) -
Expression of human DNA mismatch-repair protein, hMSH2, in patients with oral lichen planus
por: LI, HAO-BO, et al.
Publicado: (2015) -
MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases
por: Clark, Nicole, et al.
Publicado: (2013)